Revolution Medicines, Inc. (RVMD)

Market Cap	18.62B +133.9%
Revenue (ttm)	n/a
Net Income	-960.98M
EPS	-5.19
Shares Out	193.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,569,747
Open	97.84
Previous Close	97.33
Day's Range	95.97 - 99.01
52-Week Range	29.17 - 124.49
Beta	1.00
Analysts	Strong Buy
Price Target	102.63 (+6.56%)
Earnings Date	Feb 26, 2026

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 809
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Analyst Summary

According to 16 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $102.63, which is an increase of 6.56% from the latest price.

Price Target

$102.63

(6.56% upside)

Analyst Consensus: Strong Buy